Covid19, Inflammation, Kidney Diseases, SARS-CoV Infection
Conditions
Keywords
Biomarkers, Outcomes, Inflammation, suPAR, C-reactive protein, Interleukin-6
Brief summary
To better understand the role of inflammation in COVID-19, we established the Michigan Medicine COVID-19 Cohort (M2C2). M2C2 is a funded and ongoing cohort which has currently enrolled over 1500 adult patients (≥18 years) with severe COVID-19 admitted at the University of Michigan. The purpose of M2C2 is to define the in-hospital course of these patients and understand the role of inflammation as a determinant of organ injury and outcomes in COVID-19.
Detailed description
The Michigan Medicine COVID-19 Cohort is a prospective observational cohort study of patients hospitalized specifically for COVID-19 at the University of Michigan Health System in Ann Arbor. Medical records of all consecutive patients with a positive SARS-CoV-2 are reviewed, and patients with confirmed SARS-CoV-2 infection but not primarily admitted for COVID-19 were excluded. Biologic samples of patients enrolled in M2C2 were collected, and clinical characteristics including in-hospital outcomes were characterized in detail. Biomarkers measured include, but not be limited to, soluble urokinase plasminogen activator receptor (suPAR), high sensitive C reactive protein (hs-CRP), brain natriuretic protein (BNP), high sensitive troponin T (hsTnT), interleukin 6 (IL-6), osteopontin, a2-antiplasmin.
Interventions
DIAGNOSTIC_TESTBiomarkers of inflammation
Biomarkers were measured on blood samples collected within 48 hours of admission
Sponsors
University of Michigan
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Confirmed SARS-CoV-2 infection * Hospitalized primarily for the treatment of COVID-19
Exclusion criteria
* SARS-CoV-2 positive but hospitalized for non-COVID-19 reasons
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Death, need for mechanical ventilation or need for dialysis | Total duration of the Covid-19 hospitalization, up to 1 year | The primary outcome is a composite endpoint, which is defined as the need for mechanical ventilation, the need for dialysis, or in-hospital death. |
Secondary
| Measure | Time frame |
|---|---|
| All-cause death | Total duration of the Covid-19 hospitalization, up to 1 year |
| Need for mechanical ventilation | Total duration of the Covid-19 hospitalization, up to 1 year |
| Need for dialysis | Total duration of the Covid-19 hospitalization, up to 1 year |
Other
| Measure | Time frame |
|---|---|
| Length of hospitalization | Total duration of the Covid-19 hospitalization, up to 1 year |
Countries
United States
Outcome results
None listed